In addition, the levels of phosphorylation of JAK2 and downstream STAT3/5 factors in primary peripheral blood mononuclear cells from MPN patients carrying the JAK2V617F mutation were also analyzed, and the results indicated significant inhibition by ZT55. This evidence concerns the gene JAK2 and myeloproliferative disorder.